CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00862030
First received: March 13, 2009
Last updated: August 4, 2011
Last verified: August 2011
  Purpose

Radiotherapy (RT) treatment to the chest is a standard way of trying to decrease symptoms like cough or shortness of breath. Before any RT can be delivered, it must be planned, either using conventional x-rays ("fluoroscopy") or using computer tomography ("CT") scanning. This study is being done because the investigators do not know which of these two common ways of RT planning is better for balancing both treating the cancer and decreasing side effects.


Condition Intervention
Non-small Cell Lung Cancer
Procedure: CT- simulation scan

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Comparison of Two-versus Three-Dimensional Treatment Planning for Patients Receiving Chest Radiotherapy for Symptom Control

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Estimated Enrollment: 20
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Study Cohort
Procedure: CT- simulation scan
Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically

Detailed Description:

Standard RT planning will be performed under conventional simulation, followed by CT-simulation (for study purposes only). Retrospectively, 3D treatment fields will be designed using the CT-simulation data, and compared to the actual treatment fields planned using x-rays. Coverage of the tumour volume will be assessed, together with doses, field sizes and beam positions, to determine relative undercoverage of tumour and overcoverage of normal tissue between the two planning methods, if any.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

20

Criteria

Inclusion Criteria:

  • Patients with local symptoms secondary to histologically-confirmed non-small cell lung cancer
  • Patients who will be receiving palliative-intent external beam radiotherapy
  • Patients who are clinically appropriate for conventional radiotherapy planning
  • Patients who can provide written informed consent

Exclusion Criteria:

  • Patients who cannot provide written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00862030

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Dr. Alysa Fairchild, MD FRCPC AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: Dr.Alysa Fairchild, Alberta Cancer Board
ClinicalTrials.gov Identifier: NCT00862030     History of Changes
Other Study ID Numbers: 24639
Study First Received: March 13, 2009
Last Updated: August 4, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
Palliative radiotherapy
Treatment planning
Non-small cell lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014